Back to Journals » Neuropsychiatric Disease and Treatment » Volume 6 » Issue 1

Polyclonal light chains in cerebrovascular disease

Authors Fiori P, Luigi MG, Iurato L, Tammaro C, Esposito G, Monaco A

Published 24 August 2010 Volume 2010:6(1) Pages 533—537

DOI https://doi.org/10.2147/NDT.S7529

Review by Single-blind

Peer reviewer comments 3


Patrizia Fiori1, Maria Giannetti Luigi2, Linda Iurato1, Carminantonio Tammaro3, Gigliola Esposito3, Antonio Monaco1
1Central Operative Unit of Neurology (Dir. A Monaco), 2Infantile Neuropsychiatry and Social Service (Dir. LM Giannetti), 3Laboratory (Dir. CA Tammaro), ASL AV, Civil Hospital of Ariano Irpino, University of Naples, Italy

Abstract: Altered membrane permeability is a hallmark of inflammation and ischemia with systemic spreading. Renal dysfunction is a risk factor for cardiovascular, cerebrovascular, and metabolic diseases. The aim of the present study was to assess proteinuria and urinary polyclonal light chains in acute stroke and chronic cerebrovascular disease compared with other neurologic diseases. Our results showed significantly increased levels of urinary polyclonal light chains in cerebrovascular disease compared with other neurologic diseases. The highest values of urinary polyclonal κ chains were found in acute stroke compared with chronic cerebrovascular disease and other neurologic diseases, while the level of λ chains was mainly increased in chronic cerebrovascular diseases. The shift to chronic renal failure seems to be signaled by a decreased polyclonal light chain/creatinemia ratio. The absence of a significant correlation with blood pressure and other seric parameters suggests that polyclonal light chains are an early marker of reversible vascular impairment with renal dysfunction before progression to irreversible renal failure and need for dialysis and/or intensive care.

Keywords: polyclonal light chains, cerebrovascular disease, renal failure

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]